Hightide Therapeutics Inc. closed a $107 million series C round that will advance multiple global development programs for lead candidate HTD-1801, including a phase III trial in type 2 diabetes.
Hightide Therapeutics Inc. closed a $107 million series C round that will advance multiple global development programs for lead candidate HTD-1801, including a phase III trial in type 2 diabetes.
Bayer AG has synthesized new furoindazole derivatives acting as G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of inflammation, metabolic disorders, autoimmune and lung diseases, among others.
Regor Therapeutics Group and Eli Lilly and Co. have inked a collaboration and licensing deal to co-develop therapies for metabolic disorders in a deal worth more than $1.5 billion. Under terms of the agreement, Lilly is gaining access to Regor IP to support its development of therapies for obesity and diabetes.
